GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (FRA:MLZ) » Definitions » Institutional Ownership

MediPharm Labs (FRA:MLZ) Institutional Ownership : 0.71% (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is MediPharm Labs Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MediPharm Labs's institutional ownership is 0.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MediPharm Labs's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MediPharm Labs's Float Percentage Of Total Shares Outstanding is 0.00%.


MediPharm Labs Institutional Ownership Historical Data

The historical data trend for MediPharm Labs's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Institutional Ownership Chart

MediPharm Labs Historical Data

The historical data trend for MediPharm Labs can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 0.73 0.72 0.72 0.72 0.72 0.72 0.71 0.71 0.71 0.71

MediPharm Labs Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


MediPharm Labs Business Description

Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

MediPharm Labs Headlines

No Headlines